ReviewInternational journal of molecular sciences2020
The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Prognostic value of RANK signalling in breast cancer: a systematic review and meta-analysis.BMJ open · 2025Pooled it
- Association between maternal serum RANKL and adverse birth outcomes: a prospective cohort study.Annals of medicine · 2026Article
- The Role of HER2 and RANK in Breast Cancer and New Therapeutic Approaches With Denosumab, Anti-HER2 Antibodies and Immunotherapy.Journal of cellular and molecular medicine · 2026Article
- Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Review
- OncoTheradJournal of cancer research and clinical oncology · 2023Article
- How has the field of metastatic breast cancer in bones evolved over the past 22 years?Journal of bone oncology · 2023Article
- Molecular Target and Action Mechanism of Anti-Cancer Agents.International journal of molecular sciences · 2023Article
- CAR-T cells targeting HLA-G as potent therapeutic strategy for EGFR-mutated and overexpressed oral cancer.iScience · 2023Article
- Biomaterial-assisted tumor therapy: A brief review of hydroxyapatite nanoparticles and its composites used in bone tumors therapy.Frontiers in bioengineering and biotechnology · 2023Review
- Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments.Pharmaceutics · 2022Article
- Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.Journal of bone oncology · 2022Review
- Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers.International journal of molecular sciences · 2022Article
- New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.Molecules (Basel, Switzerland) · 2021Review
- Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis.Cells · 2021Review
- Immuno-PET Molecular Imaging of RANKL in Cancer.Cancers · 2021Article
- Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.Frontiers in immunology · 2021Article
- Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.Journal of immunology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The receptor activator of nuclear factor-κB (RANK) and the RANK ligand (RANKL) were reported in the regulation of osteoclast differentiation/activation and bone homeostasis. Additionally, the RANKL/RANK axis is a significant mediator of progesterone-driven mammary epithelial cell proliferation, potentially contributing to breast cancer initiation and progression. Moreover, several studies supported the synergistic effect of RANK and epidermal growth factor receptor (EGFR) and described RANK's involvement in epidermal growth factor receptor 2 (ERBB2)-positive carcinogenesis. Consequently, anti-RANKL treatment has been proposed as a new approach to preventing and treating breast cancer and metastases. Recently, RANKL/RANK signaling pathway inhibition has been shown to modulate the immune environment and enhance the efficacy of anti-CTLA-4 and anti-PD-1 monoclonal antibodies against solid tumors. Clinical and experimental trials have emerged evaluating RANKL inhibition as an enhancer of the immune response, rendering resistant tumors responsive to immune therapies. Trials evaluating the combinatorial effect of immune checkpoint inhibitors and anti-RANKL treatment in double-positive (RANK+/ERBB2+) patients are encouraging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.